COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.

Also called NCT05633810

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 10,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05633810
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Canada, Denmark, Finland, France, Greece, Italy, Portugal (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05633810. Randomized; quadruple masking; primary purpose prevention. Start 2022-12-21 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
Acronym
COLCOT-T2D
Condition
Diabete Type 2
Condition
Cardiovascular Diseases
Intervention (Drug)
Aspirin
Intervention (Drug)
Aspirin Placebo
Intervention (Drug)
Colchicine
Intervention (Drug)
Colchicine Placebo
Lead sponsor
Montreal Heart Institute (class: other)

Record details

Record id
cardio:ct-nct05633810
Content hash
ae0cc9b370544816908de8aae1fa1dfd07cfa4d9656ae79b49b2d464efb647d2